Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 6 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Acceleron Pharma Inc. has 9 pending office actions in Biotechnology & Pharmaceuticals. The portfolio involves 8 examiners across 6 art units, indicating broad examination coverage with some repeated examiner or art-unit participation. This structure requires centralized docket oversight and matter-specific substantive review.
BERHANE, SELAM is the busiest examiner, with 2 pending matters. That relationship is the clearest point for monitoring consistency in claim interpretation and response practice. The remaining prosecution activity is distributed across the other identified assignments, so counsel should track art-unit patterns without treating the portfolio as governed by one examination approach.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 3 (33%) |
| Multi-statute (no §101) | 4 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERHANE, SELAM | 2 | 59.1% | +56.4% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | FISCHER, JOSEPH | 26d |
| 18328410 | TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME | BERHANE, SELAM | 70d |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | — |
| 18236082 | TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF | LI, RUIXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | FISCHER, JOSEPH | 26d |
| 18328410 | TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME | BERHANE, SELAM | 70d |
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | CHANDRA, GYAN | — |
| 18683894 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | SZPERKA, MICHAEL EDWARD | — |
| 18580425 | ACTRII PROTEINS AND USES THEREOF | STOICA, ELLY GERALD | — |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | — |
| 18549474 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | BERHANE, SELAM | — |
| 18549461 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1674 | 2 |
| 1641 | 2 |
| 1675 | 2 |
| 1647 | 1 |
| 1654 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | CHANDRA, GYAN | 1674 | DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18683894 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | SZPERKA, MICHAEL EDWARD | 1641 | §102§103DP | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18580425 | ACTRII PROTEINS AND USES THEREOF | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | 1654 | §103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18549474 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | BERHANE, SELAM | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18549461 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | HADDAD, MAHER M | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18236082 | TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF | LI, RUIXIANG | 1674 | §103§112Other | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18328410 | TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME | BERHANE, SELAM | 1675 | §103§112 | Non-Final OA | 70d | Pending | Jun 02, 2023 |
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | FISCHER, JOSEPH | 1658 | §102§103§112Other | Non-Final OA | 26d | Pending | May 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAcceleron Pharma Inc. has 9 pending office actions as of October 2026, spread across 6 art units and 8 examiners.
Selam Berhane has the most, with 2 of Acceleron Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
